Brazil’s Anvisa enacts role as overseer of product information and advertising
This article was originally published in Clinica
Executive Summary
Brazil’s Anvisa has formally become the regulator of the “propaganda and advertising” activities of the healthcare products industry. The changes have come through an amendment of the 2006 act that sets out its responsibilities and activities as regulator of medical devices, pharmaceuticals and other healthcare supplies.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.